Company intelligence / Profile preview
EBViously
Munich, Bavaria, Germanyebv-iously.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EBViously is a German biotechnology company spun off from Helmholtz Munich, dedicated to developing a first-in-class vaccine against the Epstein-Barr Virus (EBV). Utilizing a proprietary virus-like particle (VLP) platform, the company aims to prevent infectious mononucleosis and long-term EBV-associated complications such as multiple sclerosis and various cancers. Their lead candidate, EBV-001, is designed to mimic the structure of the virus without containing infectious genetic material, potentially offering a high safety profile and broad immune response. The company is currently advancing its lead program toward clinical trials to address a significant unmet medical need, as no EBV vaccine is currently approved.
- Therapeutic areas
- Infectious DiseasesOncologyNeurology
- Modalities
- VaccineVirus-like particle
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Helmholtz Munich
Beyond the preview
Go deeper on EBViously.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBViously.